Guggenheim Capital LLC Sells 24,035 Shares of Radius Health (RDUS)

Guggenheim Capital LLC lessened its holdings in shares of Radius Health (NASDAQ:RDUS) by 25.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 71,344 shares of the biopharmaceutical company’s stock after selling 24,035 shares during the quarter. Guggenheim Capital LLC’s holdings in Radius Health were worth $2,265,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Consonance Capital Management LP bought a new position in Radius Health during the fourth quarter valued at approximately $84,168,000. TimesSquare Capital Management LLC raised its position in Radius Health by 16.2% during the fourth quarter. TimesSquare Capital Management LLC now owns 1,871,445 shares of the biopharmaceutical company’s stock valued at $59,456,000 after acquiring an additional 261,080 shares in the last quarter. Hudson Bay Capital Management LP raised its position in Radius Health by 33.3% during the fourth quarter. Hudson Bay Capital Management LP now owns 200,000 shares of the biopharmaceutical company’s stock valued at $6,354,000 after acquiring an additional 50,000 shares in the last quarter. Candriam Luxembourg S.C.A. raised its position in Radius Health by 37.3% during the fourth quarter. Candriam Luxembourg S.C.A. now owns 195,000 shares of the biopharmaceutical company’s stock valued at $6,195,000 after acquiring an additional 53,000 shares in the last quarter. Finally, Eversept Partners LLC bought a new position in Radius Health during the fourth quarter valued at approximately $6,179,000.

How to Become a New Pot Stock Millionaire

In other news, major shareholder Growth N. V. Biotech purchased 50,000 shares of the company’s stock in a transaction dated Thursday, April 5th. The shares were bought at an average price of $36.58 per share, with a total value of $1,829,000.00. Following the completion of the transaction, the insider now directly owns 5,903,799 shares in the company, valued at approximately $215,960,967.42. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Growth N. V. Biotech purchased 80,000 shares of the company’s stock in a transaction dated Friday, March 2nd. The stock was purchased at an average cost of $32.52 per share, for a total transaction of $2,601,600.00. Following the transaction, the insider now owns 5,853,799 shares of the company’s stock, valued at $190,365,543.48. The disclosure for this purchase can be found here. In the last three months, insiders bought 205,000 shares of company stock worth $7,009,100. Insiders own 15.00% of the company’s stock.

Several equities analysts recently weighed in on RDUS shares. Morgan Stanley started coverage on shares of Radius Health in a research report on Monday, January 29th. They set an “overweight” rating and a $57.00 price objective on the stock. Zacks Investment Research lowered shares of Radius Health from a “hold” rating to a “sell” rating in a research report on Tuesday, January 2nd. Cantor Fitzgerald reaffirmed a “buy” rating and set a $58.00 price objective on shares of Radius Health in a research report on Thursday, January 18th. JPMorgan Chase cut their price objective on shares of Radius Health from $70.00 to $60.00 and set an “overweight” rating on the stock in a research report on Monday, February 12th. Finally, BidaskClub raised shares of Radius Health from a “strong sell” rating to a “sell” rating in a research report on Wednesday, December 27th. Seven investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Radius Health presently has a consensus rating of “Buy” and an average target price of $52.10.

NASDAQ:RDUS opened at $34.00 on Friday. Radius Health has a 12 month low of $24.66 and a 12 month high of $49.16. The company has a market capitalization of $1,608.33, a PE ratio of -5.86 and a beta of 1.25. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.96 and a current ratio of 5.04.

Radius Health (NASDAQ:RDUS) last released its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($1.59) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.43) by ($0.16). The firm had revenue of $7.66 million for the quarter, compared to the consensus estimate of $7.37 million. During the same quarter last year, the company posted ($1.22) earnings per share. The firm’s revenue for the quarter was up 666.0% on a year-over-year basis. analysts predict that Radius Health will post -5.07 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Guggenheim Capital LLC Sells 24,035 Shares of Radius Health (RDUS)” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/15/guggenheim-capital-llc-sells-24035-shares-of-radius-health-rdus.html.

Radius Health Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Want to see what other hedge funds are holding RDUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Radius Health (NASDAQ:RDUS).

Institutional Ownership by Quarter for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply